The federal 340B Drug Pricing Program, designed to help safety-net providers offer discounted medications to underserved and uninsured patients, has come under scrutiny in New York for allegedly increasing healthcare costs for employers and working families instead of aiding its intended beneficiaries. Critics argue that the program has been exploited by large hospitals, which purchase drugs at reduced prices but then bill insurers and health plans at higher rates, profiting from the difference.

According to a recent report by the American Benefits Council, spending tied to the 340B program has grown dramatically nationwide, with hospital drug purchases under the program jumping from $5 billion in 2010 to $66 billion in 2023. This expansion is attributed in part to the proliferation of contract pharmacy arrangements, many of which are located in more affluent areas rather than communities with high levels of poverty or unmet medical needs.

The unchecked growth of the 340B program has raised concerns about its impact on overall healthcare spending. An analysis cited by the American Benefits Council estimates that New York state employee health plans face approximately $89 million annually in markups related to 340B-priced drugs, reflecting a 146 percent increase over discounted costs. This contributes to higher insurance premiums, deductibles, and out-of-pocket expenses for workers and their families.

Critics caution that the program, originally intended to help smaller, resource-limited providers stretch their budgets to serve vulnerable populations, has instead become a substantial revenue source for larger hospital systems. They argue that revenues generated from 340B discounts are not required to be reinvested in patient care or to directly assist the needy, which undermines the program’s foundational purpose.

Amid ongoing state budget negotiations, a provision in the New York State Senate’s one-house budget proposal has drawn particular attention for preserving limited transparency around 340B activities within the state. Opponents of this measure contend that it would facilitate further expansion of the program without adequate oversight, ultimately driving up healthcare costs rather than improving affordability.

Advocates for reform are urging the New York Legislature and Governor Kathy Hochul to remove language that supports the program’s unchecked growth and instead adopt reporting requirements that would clarify how hospitals use their 340B-generated revenues. They maintain that increased transparency could inform federal efforts to modernize the program, ensuring it functions as intended without escalating costs for employers and employees.

Supporters of the 340B program defend its role in aiding healthcare access for underserved populations but acknowledge the need for reforms to prevent misuse. Ultimately, responsibility for program oversight and reform rests with Congress, though state policymakers’ decisions can influence the direction of 340B implementation locally.

As debate continues, stakeholders emphasize the importance of balancing the original goals of the 340B program with concerns about its financial impact on New Yorkers, particularly working families who bear the burden of rising healthcare costs.